Publications [#330243] of Michael J. Therien

Papers Published

  1. Prasit, P; Wang, Z; Brideau, C; Chan, CC; Charleson, S; Cromlish, W; Ethier, D; Evans, JF; Ford-Hutchinson, AW; Gauthier, JY; Gordon, R; Guay, J; Gresser, M; Kargman, S; Kennedy, B; Leblanc, Y; Léger, S; Mancini, J; O'Neill, GP; Ouellet, M; Percival, MD; Perrier, H; Riendeau, D; Rodger, I; Zamboni, R, "The discovery of rofecoxib, [MK 966, Vioxx, 4-(4'-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2-inhibitor.", Bioorganic & medicinal chemistry lettersJuly,, 1999, 9(13), 1773-1778 [doi].
    (last updated on 2026/01/19)

    Abstract:
    The development of a COX-2 inhibitor rofecoxib (MK 966, Vioxx) is described. It is essentially equipotent to indomethacin both in vitro and in vivo but without the ulcerogenic side effect due to COX-1 inhibition.